Recent Publications

• Severe Fatigue and Persistent Symptoms at Three Months Following SARS-CoV-2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study.
  Michael Gottlieb et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023
  
• Assessment of COVID-19 outbreaks in Long-Term Care Facilities.
  Carolyne Cody Bennett et al. The Journal of hospital infection 2023
  
• The next generation of coronavirus vaccines: a graphical guide
  E Callaway, Nature, February 1, 2023
  
  Vaccine developers around the world are working on dozens of ‘next-generation’ COVID-19 vaccines: not just updates of the first versions, but ones that use new technologies and platforms. These vaccines are a diverse group, but the overarching aim is to deliver long-lasting protection that is resilient to viral change. Some could protect against broader classes of coronavirus, including ones that have yet to emerge. Others might provide more potent immunity, might do so at lower doses, or might be better at preventing infection or transmission of the virus.
• The effect of previous SARS-CoV-2 infection and COVID-19 vaccination on SARS-CoV-2 Omicron infection and relation with serological response – a prospective cohort study
  B de Gier et al, MEDRXIV, January 31, 2023
  
  Our results showed that hybrid immunity is more protective against infection with SARS-CoV-2 Omicron than vaccine-induced immunity, up to at least 30 weeks after the last immunizing event. Among those with hybrid immunity, the sequence and number of immunizing events was not found to be of importance, and its protective effect was partly explained by circulating S-antibodies.
• A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
  P Dogra et al, MEDRXIV, January 31, 2023
  
• A novel TCNN-Bi-LSTM deep learning model for predicting sentiments of tweets about COVID-19 vaccines.
  Aslan Serpil, et al. Concurrency and computation : practice & experience 2023 0 0. (28) e7387
  
• Spatiotemporal evolution of COVID-19 in Portugal's Mainland with self-organizing maps.
  Duarte Igor, et al. International journal of health geographics 2023 0 0. (1) 4
  
• Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies.
  Chen Jiahui, et al. Communications in information and systems 2023 0 0. (3) 339-361
  
• Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI).
  Stirrup Oliver, et al. Open forum infectious diseases 2023 0 0. (1) ofac694
  
• Prior SARS-CoV-2 Infection and COVID-19 Vaccine Effectiveness against Outpatient Illness during Widespread Circulation of SARS-CoV-2 Omicron Variant, US Flu VE Network.
  Tartof Sara Y, et al. medRxiv : the preprint server for health sciences 2023 0 0.
  
• Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies.
  Buonsenso Danilo, et al. Frontiers in immunology 2023 0 0. 1024924
  
• Movement restrictions, vaccine coverage, and reduction of the COVID-19 incidence rate in the fourth wave of the pandemic: Analysis results from 63 provinces in Vietnam.
  Bui Hanh My, et al. Frontiers in public health 2023 0 0. 988107
  
• mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
  Buhre Jana Sophia, et al. Frontiers in immunology 2023 0 0. 1020844
  
• Bayesian sequential approach to monitor COVID-19 variants through positivity rate from wastewater.
  Montesinos-López J Cricelio, et al. medRxiv : the preprint server for health sciences 2023 0 0.
  
• Protein post-translational modification in SARS-CoV-2 and host interaction.
  Cheng Nana, et al. Frontiers in immunology 2023 0 0. 1068449
  
• Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.
  Addetia Amin, et al. bioRxiv : the preprint server for biology 2023 0 0.
  
• Targeting the Variants of COVID-19 via the Unlimited Approach.
  Ha Kyoo-Man, et al. Indian journal of microbiology 2023 0 0. 1-3
  
• SARS-CoV-2 variant-related abnormalities detected by prenatal MRI: a prospective case-control study.
  Kienast Patric, et al. The Lancet regional health. Europe 2023 0 0. 100587
  
• Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment.
  Chen Chi-Sheng, et al. PeerJ 2023 0 0. e14666
  
• Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection.
  Chen Jingran, et al. Cell reports. Physical science 2023 0 0. 101249